Precisio Biotix Therapeutics


Precisio Biotix Therapeutics develops engineered bacteriophage-derived lytic enzymes (lysins) as targeted antimicrobials for chronic and recurrent infections. The company operates a discovery-to-preclinical platform that combines computational design, machine learning, high-throughput expression and automated screening, and advances selected candidates into preclinical and early clinical use via collaborations and expanded-access INDs.

Industries

Biotechnology
Biotechnology Research

Nr. of Employees

medium (51-250)

Precisio Biotix Therapeutics


Patents

Microencapsulation of bacteriophages and related products

US-12611435-B2

View Details

Bacterial control through dispersion of bacteriophage powders

US-12396460-B2

View Details

Disinfection of bacteriophages products using supercritical carbon dioxide

US-12232492-B2

View Details

Composition comprising amino acid polymers and a bioactive agent and method of preparing thereof

US-11564894-B2

View Details

Microencapsulation of bacteriophages and related products

US-11413319-B2

View Details

Microencapsulation of bacteriophages and related products

US-10849944-B2

View Details
View All Patents

Products

Chimeric anti-staphylococcal lysin (clinical candidate for prosthetic joint infection)

A chimeric lysin engineered to target Staphylococcus spp. for treatment of chronic prosthetic joint infections; advanced to first-in-human use under expanded-access INDs.

Engineered lysin candidates for bacterial vaginosis (preclinical)

Lysins designed to selectively target Gardnerella and associated biofilms to treat or prevent bacterial vaginosis while preserving lactobacilli-dominated microbiota; funded through discovery and preclinical grants.

Engineered lysin programs for respiratory infections (discovery)

Discovery-stage lysin development targeting Gram-positive and Gram-negative pathogens implicated in lower respiratory tract infections, including hospital- and ventilator-associated pneumonia.

Topical lysin-based dermatological products (consumer and therapeutic lines)

Dermatology-focused lysin products for indications such as atopic dermatitis and acne; includes a consumer eczema product with EU market readiness and development-stage therapeutic products.

LysiThru

Machine learning platform to design, engineer, and screen lysins at high throughput.

EczePHx

Lysin-based consumer product for atopic dermatitis and eczema, targeting Staphylococcus aureus.


Services

Collaborative R&D and co-development agreements with pharmaceutical and strategic partners to advance engineered lysin candidates toward clinical use.

Coordination with clinical centers to enable single-patient expanded-access IND treatments and compassionate use programs for severe infections.

End-to-end discovery using computational design, high-throughput expression and screening to generate and prioritize lysin leads against predefined target profiles.

Expertise Areas

  • Antimicrobial drug discovery
  • Lysin engineering and development
  • Machine-learning driven protein design
  • High-throughput screening against clinical isolates
  • Show More (4)

Key Technologies

  • Machine-learning-driven protein design
  • Automated high-throughput expression and screening
  • Recombinant protein expression
  • Protein structure prediction
  • Show More (4)

News & Updates

First patient dosed with an engineered anti-staphylococcal lysin for a multidrug-resistant prosthetic joint infection under an FDA single-patient expanded-access IND filed by Mayo Clinic.

Peer-reviewed publication detailing a chimeric lysin with therapeutic potential against Staphylococcus aureus in Antimicrobial Agents and Chemotherapy.

Additional expanded-access administration reported for a chronic prosthetic joint infection with no adverse events and a culture-negative joint at one month.

Non-dilutive grant awarded to advance discovery efforts for engineered lysins targeting bacterial vaginosis pathobionts, supporting development toward preclinical testing.

Partnership to advance lysin-based antimicrobials in India, including white paper work and expanded-access programmes.

Publication in Antimicrobial Agents and Chemotherapy describing a chimeric lysin with therapeutic potential for Staphylococcus aureus infections.

View All News

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.